VidaMed wins TUNA (transurethral needle ablation) court battle with ProSurg:
This article was originally published in Clinica
Executive Summary
A US District Court has granted VidaMed's motion for summary judgment against ProSurg for "asking, encouraging or otherwise soliciting physicians to use ProSurg's Opal and Opal Flex products to treat BPH (benign prostatic hyperplasia)." The court found that VidaMed's patent 5,536,240 covering the use of radiofrequency electrodes for treatment of BPH, known as transurethral needle ablation (TUNA), was infringed. VidaMed of Freemont, California, says the decision strengthens its case in ongoing litigation between the two companies.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.